Radiolabeled benzamides are attractive candidates for targeted radiotherapy of metastatic melanoma as they bind melanin and exhibit high tumor uptake and retention. One such benzamide, N-(2-diethylaminoethyl)-4-(4-fluoro-benzamido)-5-iodo-2-methoxy-benzamide (MIP-1145), was evaluated for its ability to distinguish melanin-expressing from amelanotic human melanoma cells, and to specifically localize to melanin-containing tumor xenografts. The binding of [ 131
Introduction
The incidence of malignant melanoma is increasing faster than that of any other cancer in the United States, and The Skin Cancer Foundation estimates that ∼60,000 new cases will be diagnosed this year. Unfortunately, the prognosis for stage III and IV disease is poor. Currently, there is no effective treatment for melanoma metastases, and patients with metastatic disease have a life expectancy of 4 to 6 months. Complete surgical removal of the diseased tissue is commonly used to treat the primary tumor. However, due to early and widespread occurrence of metastases as small as 3 mm in diameter, surgery is often not curative, and chemotherapeutic options are limited with poor response rates. Current Food and Drug Administration-approved treatments for stage IV melanoma include dacarbazine, with an objective response rate of 16% (1) , and high-dose bolus interleukin 2 (IL-2; proleukin), also with an objective response rate of 16% (2) . High-dose interferon α-2b (intron A) is approved for high-risk stage II and III melanoma and has an objective response rate of 14% in stage IV disease (3) . The combination of IL-2 and interferon α-2b occasionally produces relatively long durations of response but do not benefit enough patients to improve median survival substantially; in addition, these agents are associated with significant toxicity (4) (5) (6) (7) . The poor response rates with these regimens suggest a large unmet need for effective treatments for patients with metastatic melanoma.
The vast majority of melanomas contain the pigment melanin (8) , which is produced within cells during the metabolism of tyrosine. Melanin is found in all pigmented regions of the body, including the skin, hair, and eyes, and is also found in the inner ear and in regions of the brain, specifically within the substantia nigra (9, 10) . Melanins are biopolymers containing indole units with carboxyl functionalities and phenolic hydroxy groups (11) , which seem to have multiple homeostatic and protective functions. In the skin, melanin protects against the harmful effects of UV radiation, and melanogenesis is stimulated by DNA damage caused by UV rays. In addition, melanin plays a role in absorbing heat. Importantly, organic amines, metals, and polycyclic aromatic hydrocarbons are capable of binding melanin in normal and malignant tissues (12) . Drug-melanin associations involve a complex array of hydrogen bonding, hydrophobic and ionic interactions, and both cooperative and anticooperative binding (13, 14) . However, those interactions have not been fully characterized, partly because melanins are not well-defined chemical entities but are rather mixtures of polymers with nonhydrolyzable bonds. The physiologic significance of compound binding to normal melanotic tissue is not clear. Although it may lead to the removal of harmful substances from the body (15) , it could potentially have detrimental effects as it sequesters toxic or carcinogenic chemicals (9, 12, 14) .
Radiolabeled benzamide derivatives are known to bind melanin and exhibit high uptake and retention in melanoma cells and in mice bearing melanoma tumors (16) (17) (18) (19) (20) (21) , making them potentially effective agents for detecting melanoma in patients and for delivery of therapeutic isotopes. For the last 20 years, efforts have focused on the development of melanin-localizing benzamides that exhibit rapid washout from nontarget tissues and prolonged tumor retention for the treatment of metastatic melanoma. Here, we describe the preclinical evaluation of N-(2-diethylamino-ethyl)-4-(4-fluoro-benzamido)-5-iodo-2-methoxy-benzamide (MIP-1145), an 131 I-labeled small-molecule benzamide that may be effective for therapeutic targeting of melanin-positive melanoma.
Materials and Methods

Radiolabeling of [
131 I]MIP-1145 and [ 123 I]MIP-1145. N-(2-diethylamino-ethyl)-4-(4-fluoro-benzamido)-2-methoxybenzamide (MIP-1145 precursor, 80 μg) dissolved in acetic acid was added to thallium trifluoroacetate, Tl(TFA) 3 , in trifluoroacetic acid (TFA) in a molar ratio of 1:1.2. The solution was brought to a final volume of 0.3 mL (50% acetic acid, 50% TFA). After a 10-minute incubation at room temperature, 2.2 GBq of Na 131 I [or Na 123 I for single-photon emission computed tomography (SPECT)/computed tomography (CT)] in 10 to 20 μL of 0.1 N NaOH was added and incubated at room temperature for an additional 5 minutes. The crude reaction was diluted in formulation buffer [6% PEG-400, 2% ethanol, 6% ascorbic acid, and 3% sodium gentisate (pH 4.4)] then purified/analyzed on a Zorbax Eclipse Plus C18, 4.6 × 100 mm, 5 μm reversed phase high performance liquid chromatography (RP-HPLC) column. The column was eluted with a gradient of 25% to 60% buffer B over 10 minutes at a flow rate of 2 mL/min using 2.5% ascorbic acid (w/v)/0.5% acetic acid (v/v) in water (buffer A) and 2.5% ascorbic acid (w/v)/85% ethanol (v/v) in water (buffer B) as solvents. The product peak was collected and diluted in formulation buffer to a final concentration of 1.48 MBq/mL. The solution was filtered through a sterile Millipore Millex GV 33 mm, 0.2 μm syringe filter to yield the final product with a radiochemical purity of >95% and a specific activity as high as 55. , mice were anesthetized using 1% isoflurane gas in oxygen flowing at 0.6 L/min before and during radiopharmaceutical injection. Mice were injected through the tail vein with 37 MBq [ 123 I]MIP-1145 and imaged at 1, 4, and 24 hours postinjection with a Gamma Medica X-SPECT scanner equipped with two medium-energy collimators with a radius-of-rotation of 9 cm. The tomographic data were acquired in 64 projections over 360°at 40 seconds per projection. Following tomography, CT imaging was acquired in 512 projections to allow anatomic coregistration. Data were reconstructed using the twodimensional ordered subsets-expectation maximization algorithm. Volume rendered images were generated using Amira 5. . To monitor potential toxicity, body weight was measured daily and animals were scored for signs of distress using standard guidelines (22) . . The blood and tissue concentration-time data were computed by a noncompartment method, and pharmacokinetic parameters (maximum concentration, C max ; area under curve, AUC; mean residence time, MRT) were generated. Total clearance (CL) was calculated as CL = dose/AUC, and steady-state volume of distribution (V ss ) was calculated as V ss = MRT × CL using model 201. Regions of interest were drawn on the anterior and posterior images over the animal's total body, lung, kidney, thyroid, and eye regions at each time point (where these regions were visible). Total organ uptake was normalized to a percentage of the total body dose where the amount of retention at the first image (before voiding) was 100%. Time integrals of whole body and target organ retention were entered into OLINDA/EXM software (23) . The adult male human phantom model was used with a 4.8-hour voiding interval for the urinary bladder. The OLINDA/EXM unit density sphere model was used to estimate average dose to the eye.
Results
Radiolabeling of [
131 I]MIP-1145. The structure of MIP-1145 is shown in Fig. 1 . MIP-1145 was readily radiolabeled with 131 I or 123 I through Tl(TFA) 3 , starting with the precursor, N-(2-diethylamino-ethyl)-4-(4-fluoro-benzamido)-2-methoxybenzamide. The crude reaction solution was purified by RP-HPLC, and the product was collected in radiolysisstabilizing medium [6% ascorbic acid and 3% sodium gentisate (pH 4.5)]. Typically, a radiochemical yield of 70% to 90% with a radiochemical purity of >95% for the final product was obtained. [
131 I]MIP-1145 was stable in both saline and rat plasma (>94%) at 37°C for at least 24 hours. These data suggest a high-capacity binding of MIP-1145 to melanin such that high specific radioactivity is not necessary for effective melanoma uptake.
[ (Fig. 3) . SK-MEL-3 tumors were easily discernible at all time points examined, whereas A375 tumors were not detected. At 1 hour postinjection, diffuse tissue distribution was observed with the greatest uptake in the tumor, kidneys, gastrointestinal tract, and liver. (Fig. 4A) . Twenty-one days after implantation, SK-MEL-3 tumors reached a volume of 123 ± 8 mm 3 , and animals were randomly assigned to one of the four treatment groups. Saline treatment resulted in a linear growth rate over the first 60 days of the study. During this time, the tumor size increased >10-fold for a tumor doubling time of approximately 3 days. Several animals in the saline group either died with tumor or had to be sacrificed when the tumor reached the maximum allowed size by IACUC guidelines, 1,500 mm 3 Radiation dose estimates of [ 131 I]MIP-1145 for human organs were extrapolated from the cynomolgus monkey scintigraphic distribution data. The results of this analysis showed the target organs to be the thyroid, large intestine, and eyes, which received radiation-absorbed doses of 18, 2.8/1.1 (lower/upper), and 1.3 mGy/MBq, respectively. All other organs were predicted to receive between 0.064 and 1.1 mGy/MBq (Table 2 ).
Discussion
The value of radiolabeled benzamides for imaging melanoma through affinity for melanin was first realized in 1986 when iodine-labeled compounds under investigation for brain imaging were shown to localize to the pigmented eyes of C57BL/6 mice but not the unpigmented eyes of Wistar albino rats (26) . It was later determined that uveal melanin mediated the uptake (26) . Since these initial observations, several 123 I-labeled molecules have been examined for scintigraphic detection of malignant melanoma in patients through melanin content (16, 17, 27) . N-(2-diethylamino-ethyl 4-iodobenzamide; BZA), the first molecule to advance to clinical trials, showed a sensitivity of 81% and a specificity of 100% on a lesion site basis in patients with confirmed melanoma, thereby validating the concept (28).
More recently, several laboratories have focused on the development of benzamide analogues incorporating 131 I for radiotherapy (18) . Na 131 I is commonly used to treat thyroid cancer as it emits a high-energy (606 keV) β particle capable of ablating the cancer and its metastases. For consideration for radiotherapy, compounds must exhibit significant uptake and prolonged tumor retention and rapid washout from nontarget tissues. [
131 I]MIP-1145 was selected as a lead from a series of ring-substituted benzamides based on the level of tumor uptake in vivo, chemical stability, and aqueous solubility (25) . MIP-1145 retains a similar pharmacophore to BZA and other melanin-binding benzamides, but is modified to include a methoxy group at the 2-position and an iodine at the 5-position of the central aromatic ring, which was used here for radiolabeling with 131 I and 123 I in high radiochemical yield and purity. In addition, MIP-1145 contains a fluorobenzoate, which could potentially be radiolabeled with 18 F for monitoring the success of radiotherapy by positron emission tomography.
[ 131 I]MIP-1145 exhibited melanin-specific binding, washout from nontarget tissues, and prolonged tumor retention, making it an ideal candidate for systemic radiotherapy. The high uptake of [
131 I]MIP-1145 is in agreement with observations made using other radiolabeled benzamides (16) (17) (18) (19) (20) (21) and is consistent with the binding properties of the melanin polymer, which, unlike a typical receptor-ligand interaction, involves multiple types of associations resulting in the sequestration of large amounts of material in essentially a nonspecific, noncompetitive fashion (19) . Similarly, tumor uptake in mice bearing B16F10 xenografts was unchanged by lowering the specific activity of the [ 131 I]MIP-1145 by 1,000-fold from 55.5 TBq/mmol to 55.5 GBq/mmol, 10.17 ± 1.81 versus 9.28 ± 2.24% ID/g, respectively (25) .
Treatment of mice bearing melanin-containing SK-MEL-3 tumors with a single dose of [ melanin-containing substructures (ciliary body, retina, and choroid). The ocular substructure simulation predicted a radiation-absorbed dose of 0.2 MBq-h/MBq, with the highest radiation-absorbed dose to the ciliary body (6.8 Gy for a 3.7 GBq therapeutic dose). Using the results from external beam data, the TD 5/5 (5% incidence in 5 years) values for retinopathy and cataract induction are 45 and 10 Gy, respectively (29) . Therefore, an administered activity of 20.8 GBq would be needed to reach the retina TD 5/5 of 45 Gy for retinopathy, and an administered activity of 7.7 GBq would be needed to reach the lens TD 5 (30) (31) (32) (33) .
Although normal melanosomes have a protective function by virtue of their detoxification of reactive oxygen species (ROS), these organelles in melanoma cells are deviant inasmuch as they generate free radicals (34, 35) . This may be a result of metal binding to the characteristic pigment structure (36) or a consequence of melanin biosynthesis (37) . Chronic production of oxidative stress could contribute to the malignant transformation process (38) . Conversely, the melanoma-specific accumulation of ROS may provide a unique therapeutic target (38) , and recent evidence indicates that the ROS-inducing drug elesclomol potentiates apoptosis in melanoma cells through the induction of oxidative stress (39) . The sensitivity of melanoma cells to therapeutic schemes that promote cell death through ROS production encourages the use of ionizing radiation combined with the specificity afforded by melanoma-selective targeting using melanin-avid small molecules.
Radiation therapy has not commonly been used to treat melanoma because melanoma cells in culture have traditionally been considered radiation resistant (40) . Rofstad, in assessing the effect of radiation on several human melanoma cell lines, concluded that malignant melanoma is heterogeneous in radioresponsiveness, and therefore malignant melanomas should not be considered radiation resistant in general (41, 42) . Recently, several clinical studies have realized success using external beam radiation as a means of palliation in patients with metastatic melanoma (43, 44) , dispelling the concept that melanoma is radiation resistant. Although focused external radiation may be effective for local control, its use to treat widespread disease is obviously limited. In addition, intense local irradiation can result in significant undesirable damage to adjacent, normal tissues. Targeted radiotherapy, as exemplified here with [
131 I]MIP-1145, offers the advantage of directing the radioactive payload specifically to tumor cells through binding to a cancer-associated molecular target, thereby sparing nontarget tissues. This should be especially beneficial for patients with widespread metastases where conventional radiotherapy is not applicable.
Interestingly, moderate uptake of [ 131 I]MIP-1145 was detected in the mouse brain, reaching approximately 0.6 to 0.8% ID/g, indicating that [
131 I]MIP-1145 crosses the bloodbrain barrier. Blood-brain barrier permeability is critical for treating melanoma metastases to the brain. This is particularly encouraging given that the presence of brain metastases confers a poor prognosis, and two thirds of melanoma patients die with brain metastases (45) .
Alternative strategies to exploit melanin, melanogenesis, and the interaction of benzamides with melanin for the potential treatment of melanoma have met with early, but in some cases limited, success. In this regard, alkylating benzamides have been shown to promote tumor growth delay in preclinical models (46) , and high tumor uptake has been observed with radiolabeled acridine-conjugated benzamides (47) . Radiolabeled analogues of α-MSH peptide have also shown some promise in animal models (48) . Furthermore, radiolabeled antimelanin antibodies for imaging and treatment of melanoma have shown efficacy in preclinical models (49, 50) . However, as melanin is intracellular, antibodies are only expected to bind to necrotic tumor cells. In addition, the long circulating half-life of antibodies results in enhanced nontarget tissue exposure, often limiting the dose that can be administered. Thus, small-molecule benzamides, such as [ 131 I]MIP-1145, which freely traverse the cell membrane to reach the intracellular target and clear rapidly from the circulation and nontarget tissues, offer a more effective approach.
In summary, described here is a new radiolabeled benzamide analogue, [
131 I]MIP-1145, which as a result of its localization to melanin-expressing tumors exhibits efficacy in inhibiting melanoma growth in vivo. In light of the large unmet medical need, these data strongly support the advancement of [ 131 I]MIP-1145 to clinical trials for further evaluation as a radiotherapeutic pharmaceutical for treating patients with malignant melanoma.
